Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

Please provide the article or its content so I can generate an SEO-friendly meta description based on your guidelines.

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Under the agreement, Lilly will gain control of Adverum’s lead product candidate, Ixo-vec, a Phase 3 gene therapy designed to ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

Eli Lilly (LLY) is strengthening its presence in genetic medicine with a deal worth $261.7 million to acquire Adverum ...

Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Eli Lilly's (LLY) deal to ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) ...

Eli Lilly and Company announced a definitive agreement to acquire Aderum Biotechnologies and its leading candidate Ixo-vec. 1 ...

REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an ...